Werner Schwizer1, Dieter Menne2, Kurt Schütze3, Michael Vieth4, Reiner Goergens4, Peter Malfertheiner5, Andreas Leodolter6, Michael Fried1, Mark R Fox7. 1. University Hospital Zürich, Zürich, Switzerland ; Zurich Center for Integrative Human Physiology (ZIHP), Zurich, Switzerland. 2. Menne Biomed, Tübingen, Germany. 3. Hanusch-Hospital, Vienna, Austria. 4. Institute for Pathology, Klinikum Bayreuth, Germany. 5. Otto-von-Guericke-University, Magdeburg, Germany. 6. Klinikum der Philipps-Universität, Marburg, Germany. 7. University Hospital Zürich, Zürich, Switzerland ; Zurich Center for Integrative Human Physiology (ZIHP), Zurich, Switzerland ; NIHR Nottingham Digestive Diseases Biomedical Research Unit, Nottingham University Hospitals, Nottingham, UK.
Abstract
OBJECTIVES: This study aimed to resolve controversy regarding the effects of Helicobacter pylori eradication therapy and H. pylori infection in gastro-oesophageal reflux disease. DESIGN: A randomized, double-blind, multicentre trial was performed in patients presenting with reflux symptoms. H. pylori-positive patients were randomized to receive either antibiotics or placebo for 7 days. H. pylori-negative patient controls received placebo. All received esomeprazole 20 mg b.d. for 7 days, followed by 40 mg o.d. to complete an 8-week course, and were followed up for 32 weeks by telephone. RESULTS: In this study, 198/589 (34%) patients were H. pylori-positive and 113 H. pylori-negative patients served as controls. Baseline endoscopy revealed 63% Los Angeles grade 0A and 37% Los Angeles grade BCD oesophagitis with no difference between patient groups. Symptom improvement on esomeprazole was seen in 89%. H. pylori eradication was successful in 82%. H. pylori eradication had no effect on symptomatic relapse (hazard ratio 1.15, 95% CI 0.74-1.8; p = 0.5). Overall, H. pylori-positive patients had a lower probability of relapse compared to H. pylori-negative controls (hazard ratio 0.6, 95% CI 0.43-0.85; p = 0.004). Relapse hazard was modulated also by oesophagitis grade (BCD vs. 0A, hazard ratio 2.1, 95% CI 1.5-3.0). CONCLUSION:Relapse of gastro-oesophageal reflux disease symptoms after a course of high dose acid suppression took longer for H. pylori-positive patients than H. pylori-negative controls; however eradication therapy had no effect on the risk of relapse; ClincialTrials.gov number, NCT00574925.
RCT Entities:
OBJECTIVES: This study aimed to resolve controversy regarding the effects of Helicobacter pylori eradication therapy and H. pyloriinfection in gastro-oesophageal reflux disease. DESIGN: A randomized, double-blind, multicentre trial was performed in patients presenting with reflux symptoms. H. pylori-positive patients were randomized to receive either antibiotics or placebo for 7 days. H. pylori-negative patient controls received placebo. All received esomeprazole 20 mg b.d. for 7 days, followed by 40 mg o.d. to complete an 8-week course, and were followed up for 32 weeks by telephone. RESULTS: In this study, 198/589 (34%) patients were H. pylori-positive and 113 H. pylori-negative patients served as controls. Baseline endoscopy revealed 63% Los Angeles grade 0A and 37% Los Angeles grade BCD oesophagitis with no difference between patient groups. Symptom improvement on esomeprazole was seen in 89%. H. pylori eradication was successful in 82%. H. pylori eradication had no effect on symptomatic relapse (hazard ratio 1.15, 95% CI 0.74-1.8; p = 0.5). Overall, H. pylori-positive patients had a lower probability of relapse compared to H. pylori-negative controls (hazard ratio 0.6, 95% CI 0.43-0.85; p = 0.004). Relapse hazard was modulated also by oesophagitis grade (BCD vs. 0A, hazard ratio 2.1, 95% CI 1.5-3.0). CONCLUSION: Relapse of gastro-oesophageal reflux disease symptoms after a course of high dose acid suppression took longer for H. pylori-positive patients than H. pylori-negative controls; however eradication therapy had no effect on the risk of relapse; ClincialTrials.gov number, NCT00574925.
Authors: W H Chow; M J Blaser; W J Blot; M D Gammon; T L Vaughan; H A Risch; G I Perez-Perez; J B Schoenberg; J L Stanford; H Rotterdam; A B West; J F Fraumeni Journal: Cancer Res Date: 1998-02-15 Impact factor: 12.701
Authors: Spencer D Dorn; Lincoln Hernandez; Maria T Minaya; Carolyn B Morris; Yuming Hu; Suzanne Lewis; Jane Leserman; Shrikant I Bangdiwala; Peter H R Green; Douglas A Drossman Journal: Dig Dis Sci Date: 2010-07-30 Impact factor: 3.199
Authors: Dipti Chourasia; B R Achyut; Shweta Tripathi; Balraj Mittal; Rama D Mittal; Uday C Ghoshal Journal: Am J Gastroenterol Date: 2009-07-14 Impact factor: 10.864
Authors: J Labenz; B Tillenburg; U Peitz; J P Idström; E F Verdú; M Stolte; G Börsch; A L Blum Journal: Gastroenterology Date: 1996-03 Impact factor: 22.682
Authors: Andreas Steingoetter; Matthias Sauter; Jelena Curcic; Dian Liu; Dieter Menne; Michael Fried; Mark Fox; Werner Schwizer Journal: BMC Gastroenterol Date: 2015-09-02 Impact factor: 3.067